Last, the HELDR-KAT7 axis facilitates the expression of genes associated with GBM resistance to EGFR inhibitors (EGFRi) and targeting KAT7 or HELDR significantly enhances GBM responses to EGFRi treatments in vivo. Here, KAT7 is linked to glioblastoma.